Rifaximin treatment of pathogen-negative travelers' diarrhea

Journal of Travel Medicine

Volumn 14, Issue 1, 2007, Pages 16-19

  DuPont, Herbert L ^a,b,c,d   Haake, Robert ^e   Taylor, David N ^e   Ericsson, Charles D ^b   Jiang, Zhi Dong ^a   Okhuysen, Pablo C ^a,b   Steffen, Robert ^f  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIFAXIMIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FECES; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIAL IDENTIFICATION; STATISTICAL SIGNIFICANCE; TRAVELLER DIARRHEA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WELLBEING;

ADMINISTRATION, ORAL; ADULT; DIARRHEA; DOUBLE-BLIND METHOD; FECES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; RIFAMYCINS; TRAVEL; TREATMENT OUTCOME;

EID: 33846284518     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/j.1708-8305.2006.00084.x     Document Type: Article

References (28)

1. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001; 32:1706-1709.
2. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002; 185:497-502.
3. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21:536-541.
4. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821-1827.
5. Farthing MJG, DuPont HL, Guandalini S, et al. Treatment and prevention of travellers' diarrhoea. Gastroenterol Int 1992; 5:162-175.
6. Gorbach S, Edelman R. Travelers' diarrhea: National Institutes of Health Consensus Development Conference. Rev Infect Dis 1986; 8(Suppl 2):S109-S233.
7. DuPont HL, Ericsson CD, Mathewson JJ, et al. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. Antimicrob Agents Chemother 1992; 36:87-91.
8. DuPont HL, Reves RR, Galindo E, et al. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 1982; 307:841-844.
9. Taylor DN, Echeverria P, Blaser MJ, et al. Polymicrobial aetiology of travellers' diarrhoea. Lancet 1985; 1:381-383.
10. Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993; 16:111-118.
11. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45:212-216.
12. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy 2005; 51(Suppl 1):67-72.
13. Ericsson CD, Johnson PC, DuPont HL, et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann Intern Med 1987; 106:216-220.
14. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98:1073-1078.
15. Taylor D, Bourgeois A, Ericsson C, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006; 74:1060-1066.
16. DuPont HL, Cooperstock M, Corrado ML, et al. Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15(Suppl 1):S228-S235.
17. Jiang ZD, Mathewson JJ, Ericsson CD, et al. Characterization of enterotoxigenic Escherichia coli strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992-1997. J Infect Dis 2000; 181:779-782.
18. Murray BE, Mathewson JJ, DuPont HL, et al. Utility of oligodeoxyribonucleotide probes for detecting enterotoxigenic Escherichia coli. J Infect Dis 1987; 155:809-811.
19. Caeiro JP, Estrada-Garcia MT, Jiang ZD, et al. Improved detection of enterotoxigenic Escherichia coli among patients with travelers' diarrhea, by use of the polymerase chain reaction technique. J Infect Dis 1999; 180:2053-2055.
20. Miqdady MS, Jiang ZD, Nataro JP, et al. Detection of enteroaggregative Escherichia coli with formalin-preserved HEp-2 cells. J Clin Microbiol 2002; 40:3066-3067.
21. Vial PA, Mathewson JJ, DuPont HL, et al. Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol 1990; 28:882-885.
22. Vandenberg O, Dediste A, Houf K, et al. Arcobacter species in humans. Emerging Infect Dis 2004; 10:1863-1867.
23. Zhang G, Svenungsson B, Karnell A, et al. Prevalence of enterotoxigenic Bacteroides fragilis in adult patients with diarrhea and healthy controls. Clin Infect Dis 1999; 29:590-594.
24. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004; 10:1009-1011.
25. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805-812.
26. Johnson PC, Ericsson CD, Morgan DR, et al. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob Agents Chemother 1986; 30:671-674.
27. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449.
28. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441.